Q32 Bio Valuation
| QTTB Stock | 2.19 0.13 5.60% |
Based on Macroaxis valuation methodology, the entity appears to be overvalued. Q32 Bio owns a latest Real Value of USD1.9 per share. The recent price of the entity is USD2.19. Our model determines the value of Q32 Bio from reviewing the entity fundamentals such as price to book of 3.55 X, and Return On Asset of -0.34 as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Q32 Bio's valuation include:
Overvalued
Today
Please note that Q32 Bio's price fluctuation is abnormally volatile at this time. Calculation of the real value of Q32 Bio is based on 3 months time horizon. Increasing Q32 Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Q32 Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Q32 Stock. However, Q32 Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.19 | Real 1.9 | Target 12.0 | Hype 2.19 | Naive 2.54 |
The real value of Q32 Stock, also known as its intrinsic value, is the underlying worth of Q32 Bio Company, which is reflected in its stock price. It is based on Q32 Bio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Q32 Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Q32 Bio helps investors to forecast how Q32 stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Q32 Bio more accurately as focusing exclusively on Q32 Bio's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Q32 Bio's intrinsic value based on its ongoing forecasts of Q32 Bio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Q32 Bio's closest peers. If more than one evaluation category is relevant for Q32 Bio we suggest using both methods to arrive at a better estimate.
Q32 Bio Cash |
|
Q32 Valuation Trend
Comparing Q32 Bio's enterprise value against its market capitalization is a good way to estimate the value of Q32 Bio uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Q32 Bio Total Value Analysis
Q32 Bio is at this time anticipated to have valuation of (19.91 M) with market capitalization of 26.77 M, debt of 18.9 M, and cash on hands of . The negative valuation of Q32 Bio may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Q32 Bio fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(19.91 M) | 26.77 M | 18.9 M |
Q32 Bio Asset Utilization
One of the ways to look at asset utilization of Q32 is to check how much profit was generated for every dollar of assets it reports. Q32 Bio owns a negative utilization of current and long term assets of -0.34 %, losing USD0.00338 for each dollar of current and long term assets held by the entity. Inadequate asset utilization implies the company is being less competent with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of Q32 Bio shows how discouraging it operates for each dollar spent on its current and long term assets.Q32 Bio Ownership Allocation
The market capitalization of Q32 Bio is USD26.77 Million. The majority of Q32 Bio outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to secure positions in Q32 Bio to benefit from reduced commissions. Hence, outside corporations are subject to a different set of regulations than regular investors in Q32 Bio. Please pay attention to any change in the institutional holdings of Q32 Bio as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the entity is larger than the current market value, you may still be able to generate positive returns on investment in this company.Q32 Bio Profitability Analysis
Net Loss for the year was (47.73 M) with loss before overhead, payroll, taxes, and interest of (48.25 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Q32 Bio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Q32 Bio and how it compares across the competition.
About Q32 Bio Valuation
The stock valuation mechanism determines Q32 Bio's current worth on a weekly basis. Our valuation model uses a comparative analysis of Q32 Bio. We calculate exposure to Q32 Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Q32 Bio's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -487 K | -462.6 K | |
| Pretax Profit Margin | 7.23 | 7.59 | |
| Operating Profit Margin | 6.53 | 6.86 | |
| Net Profit Margin | 7.27 | 7.64 | |
| Gross Profit Margin | 0.98 | 0.65 |
Q32 Bio Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 9.7 M |
Q32 Bio Current Valuation Indicators
Valuation refers to the process of determining the present value of Q32 Bio and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Q32 we look at many different elements of the entity such as Q32's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Q32 Bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Q32 Bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Q32 Bio's worth.Complementary Tools for Q32 Stock analysis
When running Q32 Bio's price analysis, check to measure Q32 Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Q32 Bio is operating at the current time. Most of Q32 Bio's value examination focuses on studying past and present price action to predict the probability of Q32 Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Q32 Bio's price. Additionally, you may evaluate how the addition of Q32 Bio to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |